Integrated and first trimester prenatal screening in California: program implementation and patient choice for follow-up services

被引:35
作者
Currier, Robert [1 ]
Wu, Nerissa [1 ]
Van Meter, Karla [1 ]
Goldman, Sara [1 ]
Lorey, Fred [1 ]
Flessel, Monica [1 ]
机构
[1] Calif Dept Publ Hlth, Genet Dis Screening Program, Richmond, CA USA
关键词
FETAL NUCHAL TRANSLUCENCY; FREE BETA-HCG; DOWNS-SYNDROME; PAPP-A; RISK; 1ST-TRIMESTER; TRISOMY-18; PREGNANCY; MARKERS;
D O I
10.1002/pd.3961
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objectives The California Prenatal Screening Program serves over 350?000 women annually. This study examines utilization rates for the various screening options and patient choices regarding follow-up services. Methods The study tracked patients with first trimester positive results for Down syndrome to examine patient decisions regarding follow-up services and/or additional screening and to identify determinants of patient decisions. For first trimester screen positive women who elected further screening, second trimester integrated screening results were analyzed. The Genetic Disease Screening Program Chromosome Registry was used to identify Down syndrome cases. Results Ethnicity, but not age, was a strong predictor of acceptance of prenatal diagnosis. Approximately 47% of first trimester screen positive women opted for further screening. Among these women, 46% percent received an integrated screen negative result. All but one confirmed Down syndrome case in this cohort were still screen positive. Conclusions Data from the California Prenatal Screening Program indicate that all of the major screening modalities continue to be utilized. The wide range of choices made by women with screen positive results demonstrate the importance of including multiple options within the Program. Providing integrated screening to first trimester Down syndrome screen positive women reduced the number of unnecessary invasive procedures. (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:1077 / 1083
页数:7
相关论文
共 11 条
  • [1] ESTIMATING A WOMANS RISK OF HAVING A PREGNANCY ASSOCIATED WITH DOWNS-SYNDROME USING HER AGE AND SERUM ALPHA-FETOPROTEIN LEVEL
    CUCKLE, HS
    WALD, NJ
    THOMPSON, SG
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (05): : 387 - 402
  • [2] GDSP, 2012, PREN DIAGN CTR STAND
  • [3] Detection rate of quadruple-marker screening determined by clinical follow-up and registry data in the statewide California program, July 2007 to February 2009
    Kazerouni, Niloufar Neely
    Currier, Robert J.
    Flessel, Monica
    Goldman, Sara
    Hennigan, Colin
    Hodgkinson, Christina
    Lorey, Fred
    Malm, Linda
    Tempelis, Corinna
    Roberson, Marie
    [J]. PRENATAL DIAGNOSIS, 2011, 31 (09) : 901 - 906
  • [4] Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers
    Palomaki, GE
    Neveux, LM
    Knight, GJ
    Haddow, JE
    [J]. PRENATAL DIAGNOSIS, 2003, 23 (03) : 243 - 247
  • [5] Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome
    Palomaki, GE
    Bradley, LA
    Knight, GJ
    Craig, WY
    Haddow, JE
    [J]. JOURNAL OF MEDICAL SCREENING, 2002, 9 (01) : 43 - 44
  • [6] Comparing three screening strategies for combining first- and second-trimester Down syndrome markers
    Palomaki, Glenn E.
    Steinort, Klaus
    Knight, George J.
    Haddow, James E.
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 107 (02) : 367 - 375
  • [7] A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A
    Spencer, K
    Nicolaides, KH
    [J]. PRENATAL DIAGNOSIS, 2002, 22 (10) : 877 - 879
  • [8] Tul N, 1999, PRENATAL DIAG, V19, P1035, DOI 10.1002/(SICI)1097-0223(199911)19:11<1035::AID-PD694>3.0.CO
  • [9] 2-2
  • [10] Wald N J, 2003, Health Technol Assess, V7, P1